Madopar (Benserazide, Levodopa)

Madopar is used in the treatment of movement disorders that respond to dopaminergic therapy.

• Parkinson's disease: improves motor control and reduces rigidity and bradykinesia.
• Parkinsonian syndrome: alleviates symptoms when caused by drug‑induced or vascular factors.
• Levodopa‑responsive Parkinsonism: provides symptomatic relief in patients with fluctuating response to levodopa alone.

• Levodopa crosses the blood‑brain barrier and is enzymatically converted to dopamine, replenishing depleted central stores. Benserazide, a peripheral aromatic L‑amino acid decarboxylase inhibitor, blocks the conversion of levodopa outside the brain, increasing its central availability and minimizing peripheral side effects such as nausea and cardiovascular effects.

Adverse reactions may occur with Madopar use.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Orthostatic hypotension: dizziness upon standing.
• Dyskinesia: involuntary movements, especially with long‑term therapy.
• Insomnia: difficulty sleeping or fragmented sleep.
• Dry mouth: reduced salivation.

Serious or Rare Side Effects

• Neuroleptic malignant syndrome: life‑threatening hyperthermia and rigidity.
• Severe psychiatric disturbances: hallucinations or psychosis.
• Cardiac arrhythmias: uncommon but potentially serious rhythm disturbances.

Before initiating Madopar, consider the following safety measures.

• Assess renal and hepatic function: adjust therapy if impairment is present.
• Monitor for psychiatric symptoms: report hallucinations or mood changes promptly.
• Evaluate cardiovascular status: caution in patients with arrhythmias or low blood pressure.
• Review concomitant medications: avoid drugs that may exacerbate dopamine excess.
• Educate patients on timing of doses: maintain consistent intervals to reduce motor fluctuations.

Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Madopar can interact with several medicines, requiring careful management.

Major Interactions (Avoid)

• Non‑selective MAO inhibitors (e.g., phenelzine): risk of hypertensive crisis.
• Antipsychotics with strong dopamine blockade (e.g., haloperidol): may negate therapeutic effect.
• High‑dose pyridoxine (vitamin B6): accelerates peripheral levodopa metabolism.

Moderate Interactions (Monitor Closely)

• Antihypertensives: may potentiate orthostatic hypotension.
• SSRIs or SNRIs: monitor for serotonin syndrome when combined with MAO‑B inhibitors.
• Iron supplements or antacids: can reduce levodopa absorption; separate dosing by at least 2 hours.